RA0815

antibody from Oursmab

Targeting: VIM

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0815

Provider

Oursmab

Product name

Pritumumab (Biosimilar Reference Antibody) (VIM)

Antibody type

Monoclonal

Description

Pritumumab is a natural, fully human monoclonal antibody (IgG1 kappa) developed as an anti-cancer therapeutic. Its primary mechanism of action is the specific recognition and high-affinity binding to a cell-surface-expressed form of vimentin, particularly the ectodomain variant known as ecto-domain vimentin (EDV). Vimentin, an intermediate filament protein typically located inside cells, can be aberrantly expressed on the plasma membrane of various malignant cells, including those from brain tumors (e.g., glioblastoma), melanoma, and certain carcinomas. By targeting this tumor-associated antigen, pritumumab aims to either directly inhibit tumor cell migration and metastasis, induce antibody-dependent cellular cytotoxicity (ADCC), or potentially deliver a cytotoxic payload if used in a conjugated format.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.